Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,318.00
(
-0.83%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
101.17
(
2.42%
)
Bitcoin
69,597.60
(
-2.39%
)
News Focus
News Focus
Post# of 257288
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 171506

Sunday, 05/04/2014 9:42:19 PM

Sunday, May 04, 2014 9:42:19 PM

Post# of 257288
FDA approves GSK’s Incruse Ellipta for COPD:

http://finance.yahoo.com/news/gsk-receives-approval-incruse-ellipta-222700210.html

Incruse Ellipta is a single-agent LAMA; its active ingredient, umeclidinium, is one of the two agents in GSK’s LABA/LAMA combination, Anoro Ellipta (#msg-95105544).

It’s getting pretty hard to keep track of all the products that use the Ellipta trademark.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today